$131.47
0.75[0.57%]
Last update: 1:28PM Get Real Time Here
Merck & Co
(NYSE:MRK)Latest News for Merck & Co Stock (NYSE:MRK)
Merck & Co Stock (NYSE: MRK)
Categories: All
Friday, April 26, 2024
Thursday, April 25, 2024
- Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?Piero Cingari - 1 day ago
- Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual OutlookVandana Singh - 1 day ago
- S&P 500 Down Over 1%; Merck Increases 2024 OutlookAvi Kapoor - 1 day ago
- Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings – Here Is The Real ReasonThe Arora Report - 1 day ago
- Merck shares are trading higher after the company reported better-than-expected Q1 financial results and raised its 2024 guidance.Benzinga Newsdesk - 1 day ago
- Merck Forecasts 2024 Adjusted EPS Of $8.53-$8.65 Versus Prior Guidance Of $8.44-$8.59 And Consensus Of $8.56Benzinga Newsdesk - 1 day ago
- Merck Forecasts 2024 Sales Guidance Of $63.1B-$64.3B Versus Prior Guidance Of $62.7B-$64.2B And Consensus Of $63.82BBenzinga Newsdesk - 1 day ago
- Merck & Co Q1 2024 Adj EPS $2.07 Beats $1.88 Estimate, Sales $15.775B Beat $15.196B EstimateBenzinga Newsdesk - 1 day ago
- US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says AnalystShanthi Rexaline - 1 day ago
Wednesday, April 24, 2024
Tuesday, April 23, 2024
Sunday, April 21, 2024
Thursday, April 18, 2024
Wednesday, April 17, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Monday, April 08, 2024
Friday, April 05, 2024
Thursday, April 04, 2024
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - Apr 4, 2024, 1:35PM
- Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing DataVandana Singh - Apr 4, 2024, 10:38AM
- Merck Begins Phase 3 Clinical Trial Of MK-1084, An Investigational Oral KRAS G12C Inhibitor, In Combination With KEYTRUDA For First-Line Treatment Of Certain Patients With Metastatic Non-Small Cell Lung CancerBenzinga Newsdesk - Apr 4, 2024, 6:48AM
Wednesday, April 03, 2024
Monday, April 01, 2024
Thursday, March 28, 2024
- Looking At Merck & Co's Recent Unusual Options ActivityBenzinga Insights - Mar 28, 2024, 2:16PM
- Truist Securities Reiterates Buy on Merck & Co, Raises Price Target to $142Benzinga Newsdesk - Mar 28, 2024, 11:41AM
- Japan Index Falls While Asia And Europe Markets Rise, And Gold Exceeds $2,220 - Global Markets Today While US SleptAkanksha Bakshi - Mar 28, 2024, 7:16AM
- The European Commission Approves Merck's Keytruda In Combination With Platinum-containing Chemotherapy As Neoadjuvant Treatment, Then Continued As Monotherapy As Adjuvant Treatment, For Resectable Non-small Cell Lung Cancer At High Risk Of RecurrenceBenzinga Newsdesk - Mar 28, 2024, 6:48AM
Wednesday, March 27, 2024
- Merck Stock Soars On FDA Approval for Winrevair: Technical Analysis And Market OutlookSurbhi Jain - Mar 27, 2024, 3:00PM
- The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst SaysVandana Singh - Mar 27, 2024, 1:37PM
- Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Mar 27, 2024, 10:03AM
- Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $135 Price TargetBenzinga Newsdesk - Mar 27, 2024, 9:44AM
- Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung DiseaseVandana Singh - Mar 27, 2024, 9:20AM
- Wells Fargo Maintains Equal-Weight on Merck & Co, Raises Price Target to $135Benzinga Newsdesk - Mar 27, 2024, 8:41AM
- US Stocks Set For Rebound, Aim To Snap 3-Session Slump And Close Quarter Strong: Analyst Foresees Robust April AheadShanthi Rexaline - Mar 27, 2024, 7:13AM
- Merck shares are trading higher after the company received FDA approval for Winrevair (sotatercept) for adults with pulmonary arterial hypertension.Benzinga Newsdesk - Mar 27, 2024, 6:32AM